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Idiopathic pulmonary fibrosis (IPF) is the classic fibrosing interstitial lung disease (ILD). Although inexorably progressive, its natural history is inconsistent and unpredictable (1, 2) . This variability in the rate and severity of disease progression makes prognostication for individual patients challenging and creates significant barriers to efficient drug development. Validation of a sensitive, reproducible, and objective biomarker that accurately tracks disease progression and response to therapy would be of enormous benefit. High-resolution computed tomography (HRCT) of the chest is routinely performed in patients with suspected fibrotic lung disease and is widely available, making it a promising target for biomarker research (3) . Although there is ample evidence that HRCT provides prognostic information in IPF, qualitative visual assessment is limited by interobserver variability (4) . In contrast, computer-based methods for quantifying disease on HRCT could provide rapid, objective measurement of disease extent and change over time. We convened a group of chest radiologists and pulmonary clinicians with IPF expertise, scientists with expertise in computational image analysis, and key individuals from the pharmaceutical industry to address the optimal approach to developing image-based biomarkers for diagnosis, prognosis, and monitoring of response to therapy in IPF.
Background Imaging Endpoints and Biomarkers in IPF
The Biomarkers Definitions Working Group defines a clinical endpoint as a variable that reflects how a patient feels, functions, or survives (5, 6) . The past 3 decades of IPF clinical trial design have struggled to find a clinical primary endpoint that can be routinely used. Although all-cause mortality is a well-defined, reliable, and easy-tomeasure primary endpoint, its use in IPF is limited because of low event rates (7) . Therefore, in the absence of an ideal endpoint such as mortality, the substitution of a validated biomarker for a clinical endpoint (i.e., a surrogate endpoint) that can reliably predict the effect of the therapy can significantly improve the efficiency of IPF clinical trials (8) (9) (10) .
Although quality-of-life and functional status instruments are predictive of mortality and show promise as potential biomarkers, these measures may not reflect therapeutic impact commensurate with survival (6) . FVC is widely considered an accepted surrogate endpoint in IPF clinical trials and is routinely used as a primary endpoint. However, it is prone to missing data, it may miss important treatment effects, and, because currently approved therapies affect its rate of decline, its use in future trials may be less compelling (11) (12) (13) . Quantitative computed tomography (QCT) can be reproducibly performed across the spectrum of disease severity. Currently available data support the ability of QCT to measure baseline disease severity and progression, making it potentially an attractive surrogate endpoint (14, 15) .
Challenges in Qualifying a Biomarker
We seek to establish the clinical value of existing imaging-based biomarkers as prognostic factors (the effects of patientspecific or IPF characteristics on patient outcome), predictive factors (the effects of treatment on IPF), and surrogate endpoints in the setting of IPF (16) . As a prognostic factor, it is objectively measurable and might provide information on the likely outcome of IPF in an untreated individual. As a predictive factor, it might provide information on the likely benefit from treatment (either in terms of physiologic outcome or survival). Such predictive factors can be used to identify subpopulations of patients or specific phenotypes that are most likely to benefit from a given therapy.
Imaging biomarker development and validation. In the development and qualification of an imaging biomarker, there are three important phases: 1) development (including training of classifiers), 2) analytic validation (determination of cut points, assessment of reproducibility, and evaluation against radiologist measurements), and 3) clinical validation in which the system and its cut points are fixed and it is evaluated against outcomes in new clinical trial data. In the development phase, a supervised classification model is usually constructed using regions of interest with parenchymal abnormalities identified and classified visually by an expert thoracic radiologist. Test validation studies are then performed to estimate the variation of measurement and clarify the cut points for the intended use of the proposed biomarker. Clinical utility is tested in retrospective then prospective studies to show evidence that the effect of a therapeutic intervention on a clinical endpoint (e.g., mortality) can reliably be predicted by QCT. The final step in this process is qualification of the biomarker by regulatory bodies, such as the U.S. Food and Drug Administration, for use in therapeutic trials and routine clinical practice (17) . To date, none of the available QCT methods have completed this process.
Current Imaging Analysis Methods for IPF Evaluation Imaging Protocols
Standardized imaging acquisition is crucial for QCT (18) . Volumetric acquisition with contiguous thin section reconstruction is important, with slice thickness usually around 1 mm. Because the depth of inspiration can be a major source of variation, coaching the patient to comply with standardized breathing instructions is critical. Computed tomography (CT) radiation dose used for the acquisition is variable, but can be relatively low, and further reduced by dose modulation. For image reconstruction, a relatively "soft" kernel is used to avoid excessive noise; sharper acquisitions can also be acceptable if a denoising or kernel normalization technique is used (19) . Iterative reconstruction techniques are not recommended until the effects of this reconstruction on textural analysis can be clearly understood. To ensure that QCT measurements are comparable, patients should be imaged using the same technique, ideally on the same CT scanner, at all time points. The utility of CT phantom acquisition (20) in clinical trials has not been established but may assist with machine calibration and correct implementation of an acquisition protocol before data collection begins.
Visual Semiquantitative Scoring
A CT pattern of usual interstitial pneumonia (UIP) is associated with higher mortality in fibrotic lung disease (21) (22) (23) . In addition, the extent of fibrosis on HRCT has been consistently linked to mortality in IPF in numerous studies (4, (24) (25) (26) (27) . Most outcome studies involving HRCT in IPF have focused on the ability of baseline HRCT patterns to predict outcome, but few have evaluated the ability of serial HRCT changes over a specific follow-up period to predict outcome. Semiquantitative HRCT evaluation is prone to inter-and intraobserver variability and may be too insensitive to capture clinically important short-term changes (28) .
Despite 
Computer-based Quantitative Scoring Systems
Although computer-assisted diagnosis algorithms for classifying HRCT patterns have existed for decades (38) , recent advances in computer processing power have enabled a groundswell of renewed interest in computer-assisted HRCT image analysis. In recent years, some of these tools have been used to analyze CT imaging data in clinical trials both retrospectively and prospectively. Below is a summary of some of the available computer-based methods for quantifying disease on HRCT that have been used to evaluate clinical trial populations in IPF (Table 1 ). There is currently no consensus regarding the optimal method for QCT analysis, and this review should not be interpreted as a comparison of their strengths and limitations.
Histogram kurtosis/density measures.
The Hounsfield unit (HU) scale is a measurement of relative densities (attenuation) determined by CT. In the lung parenchyma, CT attenuation, measured in HU, is determined by the relative amounts of air, soft tissue, and blood in each volume element (voxel). The CT histogram provides a distribution of HU for an individual CT image or for the entire lung, permitting calculation of mean lung attenuation, variance, skewness, entropy, and kurtosis. Kurtosis describes the sharpness of the histogram peak and is inversely proportional to the thickness of the two tails DTA fibrosis is associated with visual assessment and baseline lung function, and change in DTA fibrosis extent on sequential scans is associated with change in function (91) 2. Greater baseline DTA score is associated with increased risk of disease progression and all-cause hospitalization (63) 3. Subjects with disease progression at visual assessment had greater DTA fibrosis extent and poorer lung function at baseline and had greater rates of change in these indexes over the follow-up period (91) 4. In two IPF clinical trial populations with sequential scans, an increase of 5.5% in DTA fibrosis extent was associated with progression determined as 5% decline in FVC (unpublished data) of the histogram. Because lung fibrosis or inflammation causes an increase in the amount of soft tissue in the lung, it will increase mean lung attenuation and thereby decrease the sharpness of the histogram peak (kurtosis) and the degree of leftward skewness of the curve (Figure 1) . Mean lung attenuation, skewness, and kurtosis can therefore be used as measures of the extent of lung fibrosis. Generally, a large value of kurtosis indicates mild fibrosis, whereas low kurtosis (i.e., close to 0 or negative) indicates moderate to severe fibrosis (39). Kurtosis and skewness of a histogram are known to be correlated with changes in FVC and overall survival in patients with IPF (15, 40) .
Adaptive Multiple Feature Method.
The Adaptive Multiple Feature Method (AMFM) is a computer-based texture analysis tool that quantifies lung parenchymal patterns on CT. During development, the AMFM tool was trained on various parenchymal patterns using 31 3 31-pixel regions of interest (image patches) extracted from CT images (41) (42) (43) . Ground truth labeling of image patches was provided by the consensus vote of a group of experienced observers (43) . During training, the AMFM narrows the texture in a training set image patch to a small number of optimal features for classification, which are then applied to a test set via a Bayesian classifier. The kappa statistic of agreement between the regions, for which most observers agreed on the pattern type, versus the AMFM tool was 0.62 (43) . This technique has been extended to three-dimensional (3D) texture analysis (44, 45) and used to explore the association between the AMFM regional characterization of the lung and outcomes in patients with IPF (46) (Figure 2 (Figure 3) . Although technical features of acquisition and reconstruction are important to reproducibility of quantitative measures, the CALIPER measures have been shown to be reproducible and robust across a wide variety of acquisition and reconstruction techniques, including low (about 1-2 mSv)-and ultra-low (0.1-0.3 mSv)-dose CT techniques with both filtered back-projection and iterative reconstruction techniques (49) .
The CALIPER tool has been used retrospectively on thousands of datasets from multiple institutions and for prospective analysis of approximately 3,000 HRCT scans acquired for the LTRC. It has been successfully used to predict survival and future physiologic change (such as FVC decline) in a variety of fibrotic lung diseases, such as IPF, fibrotic nonspecific interstitial pneumonia, hypersensitivity pneumonitis, unclassifiable ILD, and mixed processes, such as combined pulmonary fibrosis and emphysema (50) (51) (52) (53) (54) (55) . Furthermore, a CALIPER-derived HRCT measure of "pulmonary vascular-related structures" provides highly discriminative prognostic information in IPF, connective tissue disease-related ILD, hypersensitivity pneumonitis, and unclassifiable ILD. Using additional automated clustering, the CALIPER characterization has been used to phenotype disease and automatically stratify subjects into subgroups with prognostic value in 1,322 LTRC scans (56, 57) . CALIPER has also been used prospectively in a double-blind, placebocontrolled, phase II clinical trial of a novel antifibrotic drug for IPF, using spirometrically controlled HRCT at baseline and 28 weeks. The mean change in lung volumes and percentage interstitial lung abnormalities (sum of ground-glass, reticular densities, and honeycombing) was evaluated as a secondary endpoint (58) .
Quantitative Lung Fibrosis.
Quantitative Lung Fibrosis (QLF) is part of a panel of measures including quantitative honeycomb, ground-glass, and composite interstitial lung disease (QILD) scores (59) . In the discovery phase, the denoised texture features and support vector machine demonstrated robustness in quantitative features across different scanner models and in classifying normal patterns (60) . In validation, a five-step process was automated: 1) denoise, 2) voxel sampling, 3) calculate texture features, 4) run support vector machine classifier, and 5) output scores as ratios (percentage) or volumes (milliliters). Analytic validation has been reported: QLF demonstrated a good performance, with visual scoring area under the curve of 0.96 for detection and quantitation of diffuse lung disease and a short-term repeatability coefficient of 0.4% for whole lung and 2% for the most severe lobe within a subject (39, 60, 61) . The QLF classifier has used robustness-driven feature selection to improve robustness against slice thickness, reconstruction kernel, and tube current without sacrificing performance. Cut points based on the repeatability measures have been frozen, and QLF and QILD extent at baseline is prognostic of survival and FVC impairment ( Figure 4) and midlevel (bottom) coronal sections are shown in the left panels obtained from a subject with lower (top set) and a subject with higher (bottom set) proportion of lung voxels/regions characterized as representing a ground-glass reticular (GGR) texture pattern. The right panels show regional transparent color overlays representing the parenchymal characteristic determined by the AMFM from the regional image texture. A higher proportion of lung characterized as GGR on a baseline highresolution computed tomography was associated with increased risk of disease progression among subjects with IPF enrolled in a clinical therapeutic trial. Colors represent: ground glass (green), normal (white), ground glass reticular (blue), bronchovascular (brown), and honeycomb (yellow).
clustering process on a large collection of unlabeled images (62) . The network is trained as a binary classifier using radiologist-labeled regions of interest (ROIs) demonstrating normal parenchyma and UIP patterns. DTA fibrosis score is calculated as the number of ROIs classified as fibrotic divided by the total number of ROIs sampled from a lung segmentation volume ( Figure 5 ).
Analytic validation in 280 subjects enrolled in IPF Network trials showed that extent of fibrosis measured by DTA correlates with physiologic impairment at baseline (FVC % predicted r = 20.60, P , 0.001; DL CO % predicted r = 20.68, P , 0.001). Responsiveness was tested in a subset of 72 subjects with 15-month follow-up HRCT. Change in DTA score was correlated with change in FVC % predicted (r = 20.41, P , 0.001) and DL CO % predicted (r = 20.40, P , 0.001). Receiver operating characteristic analysis indicated that an increase in DTA score of 5.5% at follow-up identified subjects who experienced a 5% absolute decline in FVC % predicted (63) . In a separate retrospective cohort study of 501 subjects with IPF enrolled in an interventional clinical trial, increase in baseline DTA score was associated with increased risk of disease progression and all-cause hospitalization (unpublished data).
Functional Respiratory Imaging.
Functional Respiratory Imaging (FRI) is a combination of low-dose HRCT scans taken at inspiration and expiration and computer-based flow simulations. The data acquisition procedure includes respiratory gating using a handheld spirometer to ensure correct and repeatable lung volumes (64) .
FRI enables regional quantification of lung structure and function and is validated in obstructive lung diseases through comparisons with conventional lung function measures, isotope-based techniques, hyperpolarized helium, exercise tolerance, and patient-reported outcomes (65) (66) (67) . Test/retest data and repeated baseline scans show very low variability (1-3%) for airway volumes, blood vessel volumes, and airway resistances (68, 69) . This low variability is due to the rigorously controlled and respiratory-gated way HRCT scans are obtained, in combination with a standardized 3D reconstruction of the anatomical structures (65) (Figure 6 ). By focusing on the anatomy (e.g., airway and blood volumes) rather than individual voxels, the variability induced by noise or reconstruction algorithms associated with low-dose HRCT scans can be reduced.
Recent studies in IPF showed that disease progression, as determined by FVC decline, is associated with a reduction in CTmeasured lung volumes (R 2 = 0.80, P , 0.001) and an increase in relative airway volumes (R 2 = 0.29, P , 0.001). Changes in FVC are correlated with changes in lung volumes (R 2 = 0.18, P , 0.001) and changes in relative airway caliber (R 2 = 0.15, P , 0.001) (70) . Lobe and airway volumes can already be significantly affected by IPF, whereas conventional measures such as FVC remain within the normal (healthy) range (71) . IPF disease progression manifests itself heterogeneously in terms of FRI parameters, with the lower lobes consistently more affected than the upper lobes. In a recent small drug trial (72) using a novel autotaxin inhibitor, FVC showed a positive but nonsignificant signal of 95 ml between a treatment and placebo arm after 12 weeks of treatment. FRI parameters confirmed the treatment signal with statistical significance. Although FRI is a promising technique, additional studies need to be done to further use FRI as a standard drug development tool and to determine minimal clinically important difference.
Advantages of QCT
Visual CT features (73) , derived from twodimensional interspaced HRCT imaging in the 1980s (74) (75) (76) (77) , were primarily designed to provide qualitative information that aided diagnosis. As the focus of CT analysis in ILD moves to prognostication on volumetric baseline and longitudinal CTs, the precision, sensitivity and absence of interobserver variability associated with QCT have made it an increasingly attractive substitute for visual CT analysis. Quantifying subtle changes in CT features using computer analysis is likely to play an important role in the identification of treatment efficacy in an era of newly emerging drug therapies in fibrosing lung disease.
QCT-derived features have outperformed visual CT variables in predicting outcome across several fibrosing lung diseases with diverse radiographic patterns, demonstrating its utility is not limited to the UIP pattern (57, 78, 79) . In addition, interrogation of 3D datasets by advanced computer vision and deep learning algorithm techniques may also permit identification of novel biomarkers of disease and prognostic CT features. Rapid and reproducible QCT analysis will likely become increasingly important in following subjects with interstitial lung abnormalities identified incidentally on CT or during lung cancer screening (80) (81) (82) .
Disadvantages of QCT
QCT has several limitations. First, most published approaches involve segmentation and feature extraction on the basis of lung density (measured in HU), which is heavily influenced by CT dose, slice thickness, and reconstruction kernel, including new iterative reconstructions (59) . Second, patientrelated factors, such as inspiratory volume/effort, can significantly impact QCT feature characterization. Thorough coaching of patients regarding inspiratory effort and timing or spirometric control of studies would greatly facilitate reproducibility of results (83) but would significantly increase the complexity of performance in routine clinical practice. Establishing limits of variation, and possibly adjustment for lung volume, may help to resolve this limitation (84) . Third, the availability of a noncontrast, volumetric thin high-resolution CT dataset with a CT kernel that does not alter local HU accuracy is essential to accurate feature extraction. This may limit the utility of QCT in retrospective CT datasets, as clinical scans commonly are reconstructed with parameters that use edge-enhancing algorithms to increase the visual conspicuity of some pulmonary features.
Clinical Application of an Image-based Biomarker
The immediate applicability of QCT relates to its potential role in clinical trials. Its use may be considered in the following clinical settings: to stratify patients by disease severity, with theoretical advantages over pulmonary function tests (avoiding the confounding effect of the normal range) and visual HRCT scoring (avoiding interobserver variation), and as a longitudinal predictor of early mortality. Validation would require that serial QCT predict mortality more accurately than serial FVC.
Conclusions
There is an urgent need to develop sensitive, reproducible, and objective biomarkers in IPF that can be used to monitor disease progression and therapeutic response. QCT provides an objective measure of disease extent and an opportunity to detect subtle disease progression. Therefore, understandably, QCT has been the focus of intensive biomarker research over the past decade. However, despite a growing body of literature demonstrating the potential of QCT, several questions remain unanswered. First, it is unclear if QCT can predict response to therapy using baseline data in an individual patient with IPF (i.e., QCT is unproved as a predictive factor). Second, QCT has not been shown to reliably identify treatment failure early in a trial of therapy. Although serial QCT has been applied in clinical trials with interesting results, additional prospective biomarker studies will need to be performed to show that progression of fibrosis by QCT can be used as a surrogate outcome biomarker. n
Author disclosures are available with the text of this article at www.atsjournals.org. Figure 6 . Patient-specific reconstruction of fibrosis (green), distal airways (blue), central airways (gray), emphysema (black), and blood vessels (red) using Functional Respiratory Imaging.
